LivaNova (NASDAQ:LIVN) Price Target Lowered to $70.00 at Mizuho

by · The Cerbat Gem

LivaNova (NASDAQ:LIVN – Get Free Report) had its price objective reduced by investment analysts at Mizuho from $80.00 to $70.00 in a report released on Thursday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Mizuho’s price objective points to a potential upside of 37.25% from the company’s previous close.

Other analysts have also recently issued reports about the company. Stifel Nicolaus increased their target price on LivaNova from $70.00 to $72.00 and gave the stock a “buy” rating in a research note on Thursday, July 25th. Robert W. Baird increased their price objective on shares of LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a research report on Thursday. Needham & Company LLC reaffirmed a “buy” rating and issued a $75.00 price objective on shares of LivaNova in a research report on Thursday. Baird R W upgraded LivaNova from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 17th. Finally, The Goldman Sachs Group initiated coverage on LivaNova in a report on Friday, October 4th. They issued a “buy” rating and a $65.00 price target on the stock. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $69.17.

View Our Latest Report on LIVN

LivaNova Trading Down 0.7 %

Shares of NASDAQ LIVN traded down $0.34 during midday trading on Thursday, reaching $51.00. 35,363 shares of the stock were exchanged, compared to its average volume of 620,176. LivaNova has a 12 month low of $42.75 and a 12 month high of $64.47. The company has a market capitalization of $2.76 billion, a price-to-earnings ratio of -84.52 and a beta of 1.00. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.45 and a quick ratio of 2.94. The business has a 50-day simple moving average of $50.93 and a two-hundred day simple moving average of $53.15.

LivaNova (NASDAQ:LIVN – Get Free Report) last posted its earnings results on Wednesday, July 31st. The company reported $0.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.66 by $0.15. The firm had revenue of $318.60 million during the quarter, compared to analysts’ expectations of $305.05 million. LivaNova had a positive return on equity of 13.77% and a negative net margin of 1.37%. As a group, equities research analysts expect that LivaNova will post 2.58 EPS for the current year.

Institutional Trading of LivaNova

Several large investors have recently made changes to their positions in the company. BNP Paribas Financial Markets lifted its stake in shares of LivaNova by 88.6% in the first quarter. BNP Paribas Financial Markets now owns 42,121 shares of the company’s stock valued at $2,356,000 after buying an additional 19,783 shares in the last quarter. Driehaus Capital Management LLC lifted its position in LivaNova by 64.7% in the 2nd quarter. Driehaus Capital Management LLC now owns 544,042 shares of the company’s stock valued at $29,824,000 after acquiring an additional 213,749 shares in the last quarter. Perceptive Advisors LLC boosted its stake in LivaNova by 48.5% during the 2nd quarter. Perceptive Advisors LLC now owns 444,000 shares of the company’s stock valued at $24,340,000 after purchasing an additional 145,000 shares during the last quarter. Great Lakes Advisors LLC acquired a new position in LivaNova during the 2nd quarter valued at about $16,614,000. Finally, Quantbot Technologies LP bought a new stake in LivaNova during the 1st quarter worth approximately $994,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

About LivaNova

(Get Free Report)

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.

See Also